Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 21Neoplasms 10Brain Neoplasms 10Glioma 8Head and Neck Neoplasms 7Lymphoma 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Glioblastoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Spinal Cord Neoplasms 3Lung Neoplasms 3Stomach Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Meningioma 2Lymphoma, B-Cell 2Liver Neoplasms 2

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × Magnetic Resonance Imaging × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡